

References:

1. Cancer Stat Facts: Pancreatic Cancer. Surveillance, Epidemiology, and End Results Programs. <https://seer.cancer.gov/statfacts/html/pancreas.html>. Accessed April 8, 2019.
2. Diaz Osterman CJ, Wall NR. Curcumin and Pancreatic Cancer: A Research and Clinical Update. *Journal of Nature and Science*. 2015;1(6).
3. Epelbaum R, Schaffer M, Vizel B, et al. Curcumin and Gemcitabine in Patients with Advanced Pancreatic Cancer. *Nutrition and Cancer*. 2010;62(8): 1137-1141. doi:10.1080/01635581.2010.513802.
4. Kanai M, Yoshimura K, Asada M, et al. A Phase I/II Study of Gemcitabine-Based Chemotherapy Plus Curcumin for Patients with Gemcitabine-Resistant Pancreatic Cancer. *Cancer Chemotherapy and Pharmacology*. 2011;68(1), 157-164. doi: 10.1007/s00280-010-1470-2.
5. Pancreatic Cancer. Mayo Clinic. <https://www.mayoclinic.org/diseases-conditions/pancreatic-cancer/symptoms-causes/syc-20355421>. Published March 9, 2018. Accessed April 6, 2019.
6. Pancreatic Cancer: Statistics. Cancer.Net. <https://www.cancer.net/cancer-types/pancreatic-cancer/statistics>. Accessed April 8, 2019.
7. Pastorelli D, Fabricio AS, Giovanis P, et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. *Pharmacological Research*. 2018;132:72-79. doi:10.1016/j.phrs.2018.03.013

8. Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. *World Journal of Gastroenterology*. 2014;20(32):11142-11159. doi:10.3748/wjg.v20.i32.11142.
9. Yoshida K, Toden S, Ravindranathan P, et al. Curcumin Sensitizes Pancreatic Cancer Cells to Gemcitabine by Attenuating PRC2 Subunit EZH2, and the lncRNA PVT1 Expression. *Carcinogenesis*. 2017; 38(10):1036-1046. doi:10.1093/carcin/bgx065.